Blue Earth Therapeutics Overview

  • Status
  • Private

  • Employees
  • 26

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $76.5M

  • Investors
  • 5

Blue Earth Therapeutics General Information

Description

Operator of a radiopharmaceutical company intended to offer targeted radiotherapeutics to treat patients with cancer. The company is developing and designing radioligand therapies that deliver greater doses to tumors while sparing healthy tissue, enabling healthcare professionals to treat prostate and other forms of cancer.

Contact Information

Formerly Known As
Dibra Interchemical, Dibra
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Oxford Science Park Magdalen Centre
  • Robert Robinson Avenue
  • Oxford OX4 4GA
  • England, United Kingdom
+44 01865
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • The Oxford Science Park Magdalen Centre
  • Robert Robinson Avenue
  • Oxford OX4 4GA
  • England, United Kingdom
+44 01865

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Blue Earth Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 30-Oct-2024 $76.5M Completed Clinical Trials - Phase 2
To view Blue Earth Therapeutics’s complete valuation and funding history, request access »

Blue Earth Therapeutics Patents

Blue Earth Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026185117-A1 Registrations of images in medical applications in groups Pending 03-Mar-2025
WO-2026178064-A1 Deep learning based vessel suppression on contrast enhanced mri images Pending 18-Feb-2025
WO-2026171959-A1 Fap-targeting fluorescent probes Pending 17-Feb-2025
WO-2026171961-A1 Fap-targeting fluorescent probes Pending 17-Feb-2025
EP-4764013-A1 Recovery of gadolinium from solutions comprising gadolinium-based contrast agents Inactive 19-Dec-2024 C22B59/00
To view Blue Earth Therapeutics’s complete patent history, request access »

Blue Earth Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Blue Earth Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bracco Group Holding Company Minority
PBM Capital PE/Buyout Minority
Sands Capital Growth/Expansion Minority
Soleus Capital Asset Manager Minority
Woodline Partners Hedge Fund Minority
To view Blue Earth Therapeutics’s complete investors history, request access »

Blue Earth Therapeutics Investments & Acquisitions (11)

Blue Earth Therapeutics’s most recent deal was a PIPE with Polarean Imaging for . The deal was made on 22-May-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Polarean Imaging 22-May-2024 PIPE Diagnostic Equipment
Bracco-Eisai 31-Mar-2023 Merger/Acquisition Diagnostic Equipment
Polarean Imaging 06-Apr-2021 PIPE Diagnostic Equipment
Polarean Imaging 13-Mar-2020 PIPE Diagnostic Equipment
Blue Earth Diagnostics 01-Aug-2019 Merger/Acquisition Drug Discovery
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

Blue Earth Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
SurgVision Munich, Germany 2013
Blue Earth Diagnostics Oxford, United Kingdom 2013

Blue Earth Therapeutics FAQs

  • Where is Blue Earth Therapeutics headquartered?

    Blue Earth Therapeutics is headquartered in Oxford, United Kingdom.

  • What is the size of Blue Earth Therapeutics?

    Blue Earth Therapeutics has 26 total employees.

  • What industry is Blue Earth Therapeutics in?

    Blue Earth Therapeutics’s primary industry is Biotechnology.

  • Is Blue Earth Therapeutics a private or public company?

    Blue Earth Therapeutics is a Private company.

  • What is Blue Earth Therapeutics’s current revenue?

    The current revenue for Blue Earth Therapeutics is .

  • How much funding has Blue Earth Therapeutics raised over time?

    Blue Earth Therapeutics has raised $76.5M.

  • Who are Blue Earth Therapeutics’s investors?

    Bracco Group, PBM Capital, Sands Capital, Soleus Capital, and Woodline Partners have invested in Blue Earth Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process